Navigation Links
Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents
Date:6/9/2009

Overall Market Will Increase by a Modest $300 Million From 2008 to 2018, According to a New Report from Decision Resources

WALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the Parkinson's disease drug market, fueled by the launch of several new therapies through 2018, will be offset by generic erosion of key currently-available agents. As a result, sales of Parkinson's disease therapies will increase modestly from $2.5 billion in 2008 to $2.8 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Parkinson's Disease finds that the majority of market sales will continue to be driven by the dopamine agonist drug class that includes Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol, GlaxoSmithKline's Requip, GlaxoSmithKline/SkyePharma's Requip XL/LP/RP/Modutab and UCB/Schwarz Pharma's Neupro. However, sales of some of these agents, including Mirapex/Mirapexin/Sifrol and Requip XL/LP/RP/Modutab, will be offset by increased uptake of generic equivalents. Market growth will also be constrained by the generic erosion of other key therapies, including Novartis/Orion Pharma's Comtan/Comtess/Stalevo and Teva Pharmaceuticals/Lundbeck's Agilect/Azilect.

According to the report, market sales will also be driven by the emergence of novel agents, most notably Merck Serono/EMD Serono/Newron Pharmaceuticals' safinamide, Solvay Pharmaceuticals' pardoprunox, and Acadia Pharmaceuticals/Biovail Pharmaceuticals' pimavanserin, which will be used to treat niche Parkinson's disease populations.

The report also finds that the results of recent key clinical trials will affect the way clinicians treat patients with early Parkinson's disease.

"The results of the ADAGIO trial demonstrated the disease-modifying effects of Agilect/Azilect, making it more likely that physicians will prescribe this drug to newly-diagnosed Parkinson's disease patients," said Decision Resources Analyst Sami Fam, Ph.D. "However, the need for a more definitive and robust neuroprotective therapy remains in the indication, and this unmet need is not expected to be fulfilled over the next ten years."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources              Decision Resources, Inc.
    Christopher Comfort             Elizabeth Marshall
    781-296-2597                    781-296-2563
    ccomfort@dresources.com         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. High pollution linked to poor lung function growth in children in Mexico City
2. Researchers develop long-lasting growth hormone
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
5. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
6. AWT Management Announce Aggressive Growth and Acquisition Strategy
7. Cynosure to Present at the Maxim Group Growth Conference
8. Human C-reactive protein regulates myeloma tumor cell growth and survival
9. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
10. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
11. Spectranetics to Present at The A.G Edwards Growth Conference on September 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2018)... ... August 14, 2018 , ... Eagle Merchant ... a leading provider of residential and commercial recreational surfacing products across the country. ... with products used across a wide range of markets and customers. Founded in ...
(Date:8/11/2018)... ... ... Johns Hopkins All Children’s Hospital will make a broader commitment to ensuring ... perspective on care. At its core, this perspective focuses on ways to improve health ... or setting at the right cost. Mark Douglas "Doug" Baker, M.D., will focus on ...
(Date:8/9/2018)... SEATTLE (PRWEB) , ... August 09, 2018 , ... Lyme ... cases reported per year skyrocketing to an estimated 329,000 – a 25-fold increase since ... Trends™ , Lyme disease can be found all 50 states and the District of ...
(Date:8/9/2018)... ... August 09, 2018 , ... Thanks to the generosity of ... distributors, customers, and employees, the newly established Isagenix Legacy Foundation raised ... goal. 100 percent of the donations will fund grants to nonprofit organizations that ...
(Date:8/7/2018)... ... August 07, 2018 , ... The American ... selected to receive the 2018 Board of Directors Student Scholarship . The ... of psychiatric-mental health nursing and develop the next generation of leaders in the ...
Breaking Medicine News(10 mins):
(Date:8/7/2018)... ... August 07, 2018 , ... ... the role of Sanarus Technologies President, effective immediately. Mr. Stark will lead ... sales experience in medical device toward finding new and innovative ways to ...
(Date:8/3/2018)... ... August 03, 2018 , ... LifeWIRE’s ... ACT patents list of the 5,000-strong association of app companies and information technology ... Self-Management Compliance and Notification Method System and Computer Program Product” and subsequent patents ...
(Date:8/2/2018)... ... August 02, 2018 , ... What: The Wharton School is pleased to ... will allow up to five business reporters who cover aspects of public policy to ... year. Each funding opportunity covers the cost of tuition, course materials, most group ...
Breaking Medicine Technology: